Europe Zika Virus Testing Market

Europe Zika Virus Testing Market Size (2022 To 2027)

The zika virus testing market in Europe is expected to be valued at USD 119.4 million by 2027 from USD 81.37 million in 2022, growing at a CAGR of 7.98% from 2022 to 2027.

The presence of the zika virus in the European region and an increasing number of virus testing activities in the European region are propelling the zika virus testing market growth. According to the data published by the European Centers for Disease and Prevention, an estimated 71 zika virus cases were identified in the EU/EEA countries in 2021. Zika virus is caused by a mosquito that can be transferred from one person to another through birth or sexual transmission. In addition, due to increasing cases of travelers from one region to another, airport authorities follow strict rules in conducting a zika virus test before flying to other places, which helps market growth.

Transmission of the zika virus from the mother to the fetus during pregnancy is fuelling the need for zika virus testing and driving the market growth in Europe. This virus affects infants with microcephaly, congenital malformations, preterm birth, and miscarriage. As a result, to reduce these types of cases, every pregnant woman in the early stage must undergo the zika virus test supporting the regional market growth during the forecast period.

Furthermore, the rising adoption of technological advancements in zika virus testing and increasing demand for point-of-care diagnostic devices are anticipated to promote market growth in Europe favors the market growth. A considerable number of European companies focus on developing various testing approaches for the zika virus, aiming at early virus detection, which helps with the effective treatment of the affected patients. Furthermore, the growing R&D activities around zika virus testing, increasing support from the biopharmaceutical industry for zika virus testing, and the growing number of clinical trial centers further propel the European zika virus testing market growth.

On the other end, the high costs of the zika virus testing kits and the laboratory procedures are one of the major factors hampering the regional market growth. In addition, lack of awareness regarding the symptoms, lack of proper treatment for the virus, and lack of skilled professionals further inhibit the growth rate of the European zika virus testing market. Furthermore, lack of funding by the governments in some European countries, lack of access to the testing kits in some European countries, and slow approval process for the advanced kits are impeding the regional market growth.

This research report on the Europe zika virus testing market has been segmented and sub-segmented into the following categories.

By Test Type:

• Nucleic Acid Amplification Testing (NAAT)
• Serological Testing

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

The European market is expected to showcase healthy growth in the coming years owing to the growing investments by European governments to manufacture zika virus testing kits and increasing healthcare expenditure. The growing awareness of the zika virus is favoring the market growth in Europe. The European countries' governments support the development of the research tools developed by the PREPARE project that helps collect data on the outbreak of the zika virus and prevent further impact.

France is expected to lead the European market during the forecast period. Owing to the increasing transmission of the zika virus in France, French authorities have taken several measures to reduce or prevent zika virus transmission. As a result, public health authorities take several measures to control the mosquito population and interact with local hospitals and healthcare professionals to identify suspected cases. Furthermore, several surveys show that climate change may spread the zika virus throughout Europe, thus inducing a risk and fuelling market growth.

The UK is predicted to witness a healthy CAGR during the forecast period owing to the growing awareness programs regarding the zika virus and the test related to it among a large population in the UK. Healthcare organizations and key manufacturers provide a clear view of the occurrence and prevention of the zika virus and also provide information about the symptoms and when to conduct tests to prevent difficult situations.

KEY MARKET PLAYERS:

Altona Diagnostics, Abbott Laboratories, Biocan Diagnostics, Inc., Euroimmun, ELITechGroup, F. Hoffmann-La Roche Ltd, Genekam, Quest Diagnostics, Inc., and Chembio Diagnostic Systems, Inc. are some of the noteworthy players in the European zika virus testing market.